Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.
Pediatr Neurol. 2012 Aug;47(2):147-9. doi: 10.1016/j.pediatrneurol.2012.04.013.
We describe an infant with molybdenum cofactor deficiency, initially diagnosed as cerebral palsy. Clinical features of molybdenum cofactor deficiency, e.g., neonatal seizures, hypertonus/hypotonus, and feeding and respiratory difficulties, resemble those of neonatal hypoxic-ischemic encephalopathy. Our patient, a 2-year-old boy, presented with spastic quadriplegia and mental retardation. He manifested intractable neonatal seizures and diffuse cerebral atrophy. When admitted with bronchitis at age 18 months, his uric acid levels in blood and urine were undetectable. A urinary sulfite test revealed positive results. Further tests revealed elevated urinary levels of xanthine, hypoxanthine, and S-sulfocystein. Sequencing of the MOCS2A gene revealed heterozygosity for c.[265T>C] + [266A>G], diagnosed as molybdenum cofactor deficiency type B. Neonatal seizures, progressive cerebral atrophy, and low serum levels of uric acid may provide diagnostic clues in patients with cerebral palsy of undetermined cause.
我们描述了一例钼辅因子缺乏症婴儿,最初被诊断为脑瘫。钼辅因子缺乏症的临床特征,如新生儿癫痫、高张/低张及喂养和呼吸困难,与新生儿缺氧缺血性脑病的表现相似。我们的患者是一名 2 岁男孩,表现为痉挛性四肢瘫痪和智力迟钝。他出现了难治性新生儿癫痫和弥漫性脑萎缩。18 个月大时因支气管炎入院时,其血液和尿液中的尿酸水平无法检测到。尿亚硫酸盐试验结果呈阳性。进一步的检查显示尿中黄嘌呤、次黄嘌呤和 S-磺基半胱氨酸水平升高。MOCS2A 基因突变分析显示存在 c.[265T>C] + [266A>G]杂合突变,诊断为钼辅因子缺乏症 B 型。对于原因不明的脑瘫患儿,新生儿癫痫、进行性脑萎缩和低血清尿酸水平可能提供诊断线索。